Skip to main content
. 2005 Jan 20;115(2):428–433. doi: 10.1172/JCI23269

Figure 3.

Figure 3

Clearance of Aβ deposits by direct application of anti-Aβ antibody to the surface of the brain. (A) Aβ immunoreactivity in a coronal section from the brain of a PDAPP;YFP double-transgenic mouse that received no treatment. The mouse was fitted with a cranial window on day 0 and sacrificed 7 days later. (B) Aβ immunoreactivity in a coronal section from the brain of a PDAPP;YFP double-transgenic mouse that received treatment with an N-terminal–specific anti-Aβ antibody (20 μg of 10D5). The antibody was administered directly to the surface of the brain, directly under the cranial window, during the surgical procedure on day 0 and sacrificed 7 days later. In both A and B, the area of the brain exposed by the cranial window lies between the arrowheads. (C) A higher magnification of the cortical area exposed by the cranial window in the untreated brain shown in A. (D) A higher magnification of the cortical area exposed by the cranial window in the 10D5-treated brain shown in B. Note the region of reduced Aβ immunoreactivity within 100–200 μm below the cortical surface in the treated area. Scale bars: 250 μm.